Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2026-03-19 Epub Date: 2026-02-10 DOI:10.1016/j.vaccine.2026.128308

Lucas Dufour , Jérôme Drouin , Rosemary Dray-Spira , Stéphane Le Vu

{"title":"Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023","authors":"Lucas Dufour , Jérôme Drouin , Rosemary Dray-Spira , Stéphane Le Vu","doi":"10.1016/j.vaccine.2026.128308","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although HPV vaccination coverage has remained low in France, information on barriers to vaccination is incomplete. This nationwide study aimed to assess HPV vaccination uptake and associated factors alongside the evolving recommendations since its implementation.</div></div><div><h3>Methods</h3><div>Using data from the French National Health Data System (SNDS), all individuals aged 10–29 years were included. Annual HPV vaccination uptake between 2007 and 2023 was assessed by age group and sex. Associations between individuals' socio-demographic, healthcare use and access and medical characteristics with HPV vaccination were assessed using multivariable logistic regression models.</div></div><div><h3>Findings</h3><div>Among 27.9 million (M) individuals included, 5.9M received HPV vaccination: 3.4M (2.7M females/0.7M males) aged 10–14, 2.2M (1.9M/0.3M) aged 15–19, and 0.28M (240,000/40,000) aged 20–29. Annual vaccination uptake consistently increased since 2012, reaching up to 17.1% and 15.7% of 10–14-year-old females and males in 2023. Across all age and sex groups, socioeconomic disadvantage was associated with lower odds of vaccination (adjusted odds ratios ranging from 0.45 to 0.84 for complementary health insurance allowance beneficiaries, and from 0.55 to 0.73 for those living in the most deprived quintile of municipalities), and these disparities widened over time among females aged 10–19. While probability of HPV vaccination increased with the number of contacts with the primary healthcare system, Down syndrome, diabetes and mental health disorders were associated with decreased odds of HPV vaccination.</div></div><div><h3>Interpretation</h3><div>Until 2023, disadvantaged young people, those with limited access to healthcare or suffering from chronic illnesses, benefited less from HPV vaccination than those more privileged.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128308"},"PeriodicalIF":4.5000,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X26001167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Although HPV vaccination coverage has remained low in France, information on barriers to vaccination is incomplete. This nationwide study aimed to assess HPV vaccination uptake and associated factors alongside the evolving recommendations since its implementation.

Methods

Using data from the French National Health Data System (SNDS), all individuals aged 10–29 years were included. Annual HPV vaccination uptake between 2007 and 2023 was assessed by age group and sex. Associations between individuals' socio-demographic, healthcare use and access and medical characteristics with HPV vaccination were assessed using multivariable logistic regression models.

Findings

Among 27.9 million (M) individuals included, 5.9M received HPV vaccination: 3.4M (2.7M females/0.7M males) aged 10–14, 2.2M (1.9M/0.3M) aged 15–19, and 0.28M (240,000/40,000) aged 20–29. Annual vaccination uptake consistently increased since 2012, reaching up to 17.1% and 15.7% of 10–14-year-old females and males in 2023. Across all age and sex groups, socioeconomic disadvantage was associated with lower odds of vaccination (adjusted odds ratios ranging from 0.45 to 0.84 for complementary health insurance allowance beneficiaries, and from 0.55 to 0.73 for those living in the most deprived quintile of municipalities), and these disparities widened over time among females aged 10–19. While probability of HPV vaccination increased with the number of contacts with the primary healthcare system, Down syndrome, diabetes and mental health disorders were associated with decreased odds of HPV vaccination.

Interpretation

Until 2023, disadvantaged young people, those with limited access to healthcare or suffering from chronic illnesses, benefited less from HPV vaccination than those more privileged.

查看原文本刊更多论文

法国HPV疫苗接种及相关因素：2007年至2023年的一项全国性研究

背景：尽管法国HPV疫苗接种覆盖率仍然很低，但关于疫苗接种障碍的信息不完整。这项全国性的研究旨在评估HPV疫苗接种情况及其相关因素，以及自实施以来不断发展的建议。方法：使用法国国家健康数据系统（SNDS）的数据，纳入所有10-29岁的个体。2007年至2023年间每年HPV疫苗接种情况按年龄组和性别进行评估。使用多变量logistic回归模型评估个体的社会人口统计学、医疗保健使用和获取以及医学特征与HPV疫苗接种之间的关系。结果：在2790万人中，590万人接种了HPV疫苗，其中10-14岁3.4万人（女性270万/男性0.7万），15-19岁2.2万人（1.9万/0.3万），20-29岁0.28万人（24万/4万）。自2012年以来，年度疫苗接种率持续增加，到2023年达到10-14岁女性和男性的17.1%和15.7%。在所有年龄和性别群体中，社会经济劣势与较低的疫苗接种几率相关（补充健康保险津贴受益人的调整优势比为0.45至0.84，生活在最贫困的五分之一城市的调整优势比为0.55至0.73），并且随着时间的推移，这些差距在10-19岁的女性中扩大。虽然HPV疫苗接种的可能性随着与初级卫生保健系统接触次数的增加而增加，但唐氏综合症、糖尿病和精神健康障碍与HPV疫苗接种的可能性降低有关。解释：在2023年之前，弱势年轻人，即那些获得医疗保健有限或患有慢性疾病的年轻人，从HPV疫苗接种中受益的程度低于那些享有特权的年轻人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.